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Targeting CEA in Pancreas Cancer Xenografts
with a Mutated scFv-Fc Antibody Fragment
Mark D Girgis1,3, Tove Olafsen2, Vania Kenanova2, Katelyn E McCabe2, Anna M Wu2 and James S Tomlinson1,3*
Abstract
Background: Sensitive antibody-based tumor targeting has the potential not only to image metastatic and
micrometastatic disease, but also to be the basis of targeted therapy. The vast majority of pancreas cancers express
carcinoembryonic antigen (CEA). Thus, we sought to evaluate the potential of CEA as a pancreatic cancer target
utilizing a rapidly clearing engineered anti-CEA scFv-Fc antibody fragment with a mutation in the Fc region [anti-
CEA scFv-Fc H310A].
Methods: Immunohistochemistry (IHC) with the antibody fragment was used to confirm expression of CEA on
human pancreas cancer specimens. In vivo tumor targeting was evaluated by tail vein injection of I124-labeled anti-
CEA scFv-Fc(H310A) into mice harboring CEA-positive and -negative xenografts. MicroPET/CT imaging was
performed at successive time intervals. Radioactivity in blood and tumor was measured after the last time point.
Additionally, unlabeled anti-CEA scFv-Fc(H310A) was injected into CEA-positive tumor bearing mice and ex vivo IHC
was performed to identify the presence of the antibody to define the microscopic intratumoral pattern of
targeting.
Results: Moderate to strong staining by IHC was noted on 84% of our human pancreatic cancer specimens and
was comparable to staining of our xenografts. Pancreas xenograft imaging with the radiolabeled anti-CEA scFv-Fc
(H310A) antibody demonstrated average tumor/blood ratios of 4.0. Immunolocalization demonstrated peripheral
antibody fragment penetration of one to five cell diameters (0.75 to 1.5 μm).
Conclusions: We characterized a preclinical xenograft model with respect to CEA expression that was comparable
to human cases. We demonstrated that the anti-CEA scFv-Fc(H310A) antibody exhibited antigen-specific tumor
targeting and shows promise as an imaging and potentially therapeutic agent.
Keywords: imaging, pancreas cancer, CEA, antibody
Introduction
Pancreatic cancer is one of the most lethal cancers as
incidence approximates mortality [1]. Signs and symp-
toms that suggest pancreatic cancer are usually vague
and occur late in the disease process. Because of this,
most patients have metastatic disease at diagnosis result-
ing in an overall survival of 6% at 5 years [2]. Cure for
pancreatic cancer currently hinges upon early diagnosis
and surgical resection; however, only 10% to 20% of
patients are eligible for surgery at diagnosis due to the
presence of locally advanced cancer or metastatic
disease [3]. Even still, this cohort of patients has poor
survival due to the presence small foci of metastatic dis-
ease that is not detected by current imaging modalities.
Given our current inability to detect the true burden of
disease, pancreas cancer patients are routinely under-
staged and our local therapies are thus misguided.
These data indicate the need to develop novel strategies
to detect these small foci of disease for more accurate
staging of pancreatic cancer so that we may apply our
therapies appropriately.
One such strategy to improve our ability to detect
cancer is by using labeled antibodies targeting cancer-
specific antigens. Antibodies offer high specificity for
tumor antigens on the cell surface and thus can be used
for positron emission tomography (PET) imaging once
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radiolabeled with a positron-emitting radionuclide
(immunoPET). This offers great potential to achieve
specific molecular imaging of cancer. Although very
stable and specific, intact monoclonal antibodies are
limited for imaging purposes by their extended serum
half-life causing a high background signal. To circum-
vent this issue, recombinant, domain-deleted, antibodies
with varying size and half-life can be engineered [4].
These recombinant antibodies possess similar antigen
specificity as the parental intact antibody while exhibit-
ing faster blood clearance. We have previously described
the production of a chimeric anti-carcinoembryonic
antigen (CEA) single-chain Fv-Fc (scFv-Fc) antibody
fragment that contains a mutation in the Fc portion
(histidine at position 310 to an alanine) [5]. This muta-
tion was shown to reduce the serum half-life of the
scFv-Fc fragment from 10 days to 27 h by preventing
the interaction of the intact Fc region with the Brambell
receptor (FcRN) responsible for diverting antibodies
away from the degradation pathway in cellular lyso-
somes (Figure 1a).
CEA is a 180-kDa GPI-linked glycoprotein expressed
on the cell surface of the normal adult colon at very low
levels. However, during carcinogenesis, this oncofetal
protein becomes much more highly expressed on the
cell surface. Additionally, this protein can be shed into
the circulation and measured as a serum tumor marker,
reflective of the burden of disease [6]. High levels of
CEA expression have been noted on a variety of gastro-
intestinal epithelial tumors. Adenocarcinoma of the pan-
creas is no exception, where increased CEA expression
has been reported [6-9]. Here, we sought to investigate
the potential of CEA as a tumor target of pancreas can-
cer utilizing our anti-CEA scFv-Fc H310A antibody frag-
ment [5]. First, we validated CEA expression in our
pancreas cancer xenograft models and in human pan-
creatic cancer specimens by performing immunohisto-
chemistry (IHC) with our scFv-Fc (H310A) antibody
fragment. We then evaluated our anti-CEA scFv-Fc
(H310A) antibody fragment for in vivo antigen-specific
tumor targeting of our xenograft models with microPET
imaging. Lastly, we investigated the microscopic pattern
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Figure 1 A chimeric intact antibody and single-chain Fv-Fc (scFv-Fc) fragment. (a) Schematic representation of a chimeric intact antibody
and single-chain Fv-Fc (scFv-Fc) fragment. The table below the figure indicates the molecular weight and half-life of the antibodies. Also as
shown, mutating the Fc region of an antibody at residue 310 from a histidine to an alanine will change the half-life significantly to only 27 h.
(b) SDS-PAGE and Western blot of the anti-CEA scFv-Fc (H310A) antibody. The black arrow points to the purified antibody. (c) Size exclusion
chromatography of intact CEA antibody, Anti-CEA scFv-Fc H310 antibody, and BSA. The peak of the scFv-Fc between the intact antibody and
BSA confirms its intermediate size.
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of tumor targeting of the intravenously injected antibody
fragment with ex vivo immunolocalization studies to
detect the exact location of the fragment within the
tumor, which may have important ramifications for
development of antibody-based therapeutics.
Materials and methods
Production, purification, and characterization
Production, purification, and characterization of the
anti-CEA scFv-Fc (H310A) antibody have previously
been reported in detail [5]. Briefly, after gene assembly
and site directed mutagenesis, 1 × 107 NS0 murine mye-
loma cells were transfected by electroporation with 40
μg of the pEE12 vector containing the anti-CEA scFv-Fc
(H310A) construct and selected in glutamine-deficient
DMEM/high modified media (JRH Biosciences, Lenexa,
KS, USA) as previously described [5,10]. Cell culture
supernatants were screened by enzyme-linked immuno-
sorbent assay and Western blot for selection of high
expressing clones followed by sequential protein purifi-
cation with anion exchange and hydroxyapatite columns
by fast performance liquid chromatography (FPLC) [5].
The final concentration of protein was determined by
A280 nm using an extinction coefficient of ε = 1.4. Purity
and size of the protein was determined by SDS/PAGE,
Western blot, and size exclusion chromatography [5].
Cell lines
NS0 mouse myeloma cells were maintained with
DMEM/high modified media supplemented with 10%
fetal bovine serum (FBS, Gemini Biosciences, West
Sacramento, CA, USA), and 2 mM glutamine (Invitro-
gen, Carlsbad, CA, USA). The human pancreatic cancer
cell lines, BxPC3, Capan-1, HPAF-II, and MiaPaca-2
were obtained from the American Type Culture Collec-
tion (ATCC, Manassas, VA, USA). RPMI-1640 medium,
Iscove’s Modified Dulbecco’s medium, Eagle’s Minimum
Essential medium, and DMEM were used for BxPC3,
Capan-1, HPAF-II, and MiaPaca-2 cells, respectively. All
media was supplemented with 100 units of penicillin,
100 μg of streptomycin and 10% FBS. Only DMEM used
for MiaPaca-2 cells were additionally supplemented with
horse serum (2.5%).
Antigen quantification
The relative expression of CEA was determined for each
cell line by flow cytometry. For each cell line, 1 × 106
cells were harvested from culture and resuspended in
250 μl of phosphate-buffered saline/1% fetal bovine
serum (PBS/1%FBS). Primary, intact mouse anti-CEA
antibody (Abcam, Cambridge, MA, USA) was added in
abundance (4 μg) and incubated for 1 h. The samples
were centrifuged at 1000 g for 10 minutes, the superna-
tant was discarded, and the sample was resuspended in
250 μl of PBS/1% FBS. The secondary antibody, fluores-
cin isothiocyanate (FITC)-conjugated goat anti-mouse
IgG (Fc specific) antibody (4 μg), was incubated with
each sample for 1 h and was similarly washed and resus-
pended. Negative controls included samples with cells
only and samples with cells and secondary antibody
only. Quantitation of antigen expression for each cell
line was performed using the DAKO Qifikit according
to the manufacturer’s instructions (DAKO, Carpinteria,
CA, USA). Briefly, control beads coated with known
amounts of antibody and mimicking defined antigen
densities were incubated with FITC-conjugated goat
anti-mouse IgG (Fc specific) antibody (DAKO) and eval-
uated by flow cytometry. A standard linear regression
plot and equation was extrapolated from the mean
fluorescence intensity (MFI) of the control beads. Sam-
ples of human pancreatic cancer cells were incubated
with commercial intact mouse monoclonal anti-CEA
antibody (Invitrogen) and FITC-conjugated anti-mouse
IgG and detected by flow cytometry. The MFI of these
samples were then applied to the extrapolated equation
to determine the antibody binding capacity and thus,
based on indirect immunofluorescence, the antigen den-
sity per cell. All experiments were performed in tripli-
cate and averaged to provide reliable results.
Immunohistochemistry
Human tissue specimens were provided by the Depart-
ment of Pathology at University of California, Los
Angeles (UCLA) Medical Center under an approved
UCLA Institutional Review Board protocol. These speci-
mens were evaluated by IHC for expression of CEA
using the anti-CEA scFv-Fc(H310A) antibody fragment.
Each paraffin embedded specimen was deparaffinized
and incubated with the primary anti-CEA scFv-Fc
(H310A) antibody fragment (1:50) for 1 h. Specimens
were washed with PBS/1%Tween. Specimens were then
incubated with the secondary mouse anti-human IgG
(Fc specific) antibody (1:200) (Jackson Immunoresearch
Laboratories, West Grove, PA, USA). After another
wash, specimens were incubated with the tertiary horse-
radish peroxidase (HRP)-conjugated goat anti-mouse
IgG (Fc specific) antibody (1:400) (DAKO). Negative
control slides were only incubated with the secondary
and tertiary antibodies.
Radioiodination
Radioiodination with the positron-emitting isotope 124I
was done by the Iodo-Gen method as described [5].
Labeling reactions (0.1 to 0.2 ml) typically contained 0.1
to 0.2 mg purified protein and 0.5 to 1 mCi Na124I (IBA
Molecular, Dulles, VA, USA). Labeling efficiency was
measured by instant thin layer chromatography (TLC)
using the Tec-Control kit (Biodex Medical Systems,
Girgis et al. EJNMMI Research 2011, 1:24
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Shirley, NY, USA). Immunoreactivity was determined by
incubating the radioiodinated anti-CEA scFv-Fc
(H310A) antibody (≈100,000 cpm) with excess antigen-
positive cells such that there was an abundance of anti-
gen. After incubation and centrifugation, supernatant
was collected and measured for the presence of radioac-
tivity. The immunoreactive fraction was determined by
use of the following equation: 1-(supernatant radioactiv-
ity/total radioactivity).
Xenograft imaging and biodistribution studies
All animal handling was done under a protocol approved
by the Chancellor’s Animal Research Committee of the
UCLA. Mouse xenografts were established in 8-week-old
female nude mice (Charles River Laboratories, Wilming-
ton, MA, USA). Three tumor models were developed
with antigen-positive tumors on the left shoulder and
antigen-negative tumors on the right shoulder so that
each mouse served as its own control. Approximately 1 ×
106 cells of an antigen-positive (BxPC3, HPAF-II, Capan-
1) or -negative (MiaPaca-2) cancer cells were injected
subcutaneously (s.c.) and allowed to grow for 10 to 14
days before imaging. Lugol’s solution (0.5 ml per 100 ml
water) was added to the drinking water 24 h prior to
injection to block thyroid uptake of radioiodine. Also,
gastric lavage with 1.5 mg of potassium perchlorate in 0.2
ml of PBS 30 min prior to tail vein injection was per-
formed to block stomach uptake of radioiodine. Mice
were injected with approximately 50 μg of 124I-anti-CEA
scFv-Fc (H310A) antibody (specific activity of 2.40 μCi ±
0.005 μCi/μg) in PBS/1%FBS via the tail vein. At 4 and 20
h post-injection, the mice were anesthetized using 1.5%
to 2% isoflurane, placed on the micro positron emission
tomography (microPET) bed, and imaged with a Focus
microPET scanner (Concorde Microsystems Inc., Knox-
ville, TN, USA). Acquisition time was 10 min. All images
were reconstructed using a FBP algorithm and displayed
by the AMIDE software package [11,12]. Selected animals
were also imaged by micro computed tomography
(microCT) with the resultant images coregistered with
the microPET scans for anatomic reference. Following
the last scanning time point, animals were euthanized;
tumors and blood were harvested and weighed. Radioac-
tive uptake of organs was counted in a gamma counter
(Wizard 3″ 1480 Automatic Gamma Counter, Perkin-
Elmer, Covina, CA) for biodistribution analysis. After
decay correction, radioactive uptake in the tumor and
blood was converted to percentage of injected dose per
gram of tissue (%ID/g).
Immunolocalization
IHC staining was also performed on paraffin-embedded
sections of HPAF xenografts to evaluate for the presence
of the intravenously injected anti-CEA scFv-Fc (H310A)
antibody fragment. Mice were injected with 1 × 106 cells
s.c. for xenograft creation. Once an appropriate size was
achieved (approximately 0.5 cm), the mice were injected
with 50 μg of anti-CEA scFv-Fc(H310A) antibody via the
tail vein. After 20 h, mice were sacrificed and tumors
were harvested, placed in a dry ice/2-butane bath and
embedded in optimal cutting temperature solution. Fro-
zen tumors were cut with a cryostat into 4-μm sections,
placed on a glass slide, and fixed with 20% acetone for 20
min. After fixation, IHC staining was performed. All
tumor specimen slides were incubated for 10 min with
3% hydrogen peroxide in methanol for blocking of endo-
genous peroxidase. Tumor specimen slides were incu-
bated with the secondary mouse anti-human IgG (Fc
specific) antibody (1:200) (Jackson Immunoresearch
Laboratories) followed by the tertiary HRP-conjugated
goat anti-mouse IgG (Fc specific) antibody (1:400)
(DAKO). The positive control slides were incubated with
intact mouse anti-CEA antibody (1:50) and HRP-conju-
gated goat anti-mouse IgG (Fc specific) antibody (1:400)
(DAKO). Negative control slides were only incubated
with the secondary and tertiary antibodies. Lastly, one
slide was used for hematoxylin and eosin staining.
Results
Production, purification, and characterization
The anti-CEA scFv-Fc (H310A) antibody fragment was
expressed in murine NS0 myeloma cells. Clones produ-
cing the highest amount of antibody by Western blot
were selected for expansion. Protein was purified by
FPLC from supernatant yielded an approximate purity
of 98% by standard SDS-PAGE and Western blot (Fig-
ure 1b) [5]. Also, this scFv-Fc fragment had an elution
time from a size exclusion chromatography column
between that of the intact IgG (150 kDa) and bovine
serum albumin (66 kDa) standards confirming its inter-
mediate size of 105 kDa (Figure 1c) [5].
Antigen quantification
CEA expression was determined for four different pan-
creatic cell lines (BxPC3, HPAF-II, Capan-1, and Mia-
Paca-1) using flow cytometry (Figure 2). MiaPaca-2 was
the only human pancreatic cancer cell line tested that
had no CEA expression and thus served as our negative
control for experiments. Using the DAKO Qifikit, we
quantified antigen expression by flow cytometry. CEA
expression was approximately 230,000 (± 19,500),
285,000 (± 42,900), and 310,000 (± 45,000) antigens per
cell for the Capan-1, HPAF-II, and BxPC3 cell lines,
respectively. All studies were done in triplicate.
Immunohistochemistry
Expression of CEA on human pancreas cancer speci-
mens was evaluated by performing IHC utilizing the
Girgis et al. EJNMMI Research 2011, 1:24
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anti-CEA scFv-Fc (H310A) antibody fragment upon a
tissue microarray containing 107 1-mm-tissue cores of
pancreatic adenocarcinomas. Of the 107 cancer speci-
mens, 90 demonstrated moderate to strong staining for
CEA expression (Figure 3). Twelve specimens demon-
strated weak expression and only four specimens
showed no expression of CEA. IHC staining intensity
was similar between the majority of human pancreas
cancer specimens and mouse xenografts, both showing
strong staining. Also, normal human liver and pancreas
sections revealed no staining confirming low or no
expression on normal tissues.
Radioiodination, xenograft imaging, and biodistribution
studies
Radioiodination with 124I was performed with a labeling
efficiency of 43%. Immunoreactivity of the labeled frac-
tion was 83%. For animal studies, microPET/CT was
employed to evaluate in vivo tumor targeting ability of
the anti-CEA scFv-Fc (H310A) antibody fragment. Nude
mice with a CEA-positive tumor (Capan-1, HPAF-II,
BxPC3) and CEA-negative tumor (MiaPaca-2) were
injected via the tail vein with approximately 50 μg of
radiolabeled antibody fragment (120 μCi of radioactiv-
ity). Three mice per positive cell line were used for
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Figure 2 In vitro antigen quantification. (a) Flow cytometry of each cell line tested for evaluation of CEA expression qualitatively and
quantitatively. For each graph, the red curve corresponds to cells only, the blue curve to cells and secondary FITC-conjugated goat anti-mouse
IgG (Fc specific) antibody, and the green curve to cells, primary mouse anti-CEA antibody, and secondary FITC-conjugated goat anti-mouse IgG
(Fc specific) antibody. (b) Graph and linear regression equation of control beads used to determine antigen density per cell. The corresponding
cell line antigen density is plotted and indicated on the graph.
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imaging purposes. Average tumor weight for all positive
tumors was approximately 220 mg (range, 83 to 446
mg). Whole body microPET scans were obtained at 4
and 20 h post-injection. MicroCT was obtained at 20 h
only. Figure 4 illustrates a representative image of a
member of each animal group at 20 h. Images shown
indicate specific uptake of the radiolabeled anti-CEA
scFv-Fc (H310A) antibody fragment on the left shoulder
of the mouse where positive xenografts were grown.
There is little background activity visualized by micro-
PET. The percent of injected dose per gram of tissue for
positive tumor, negative tumor and blood for each of
the animal groups to provide objective confirmation of
the microPET images are also shown in Figure 4. Aver-
age tumor to blood ratios for Capan-1, HPAF-II, and
BxPC3 were 3.7, 3.2, and 5.2, respectively. Average posi-
tive tumor to negative tumor ratios for Capan-1 and
BxPC3 were 18.1 and 17.6, respectively. For the group
of animals with HPAF-II tumors, the negative tumor
was not identifiable upon imaging or necropsy; thus, no
data is reported for the negative tumor. Biodistribution
data for all other organs evaluated were not performed
in this study as our group has previously published
these results [5].
Immunolocalization
IHC staining was also performed on frozen tumor sec-
tions from mice harboring HPAF-II xenografts after tail
vein injection of 50 μg of the unlabeled or “cold” anti-
CEA scFv-Fc (H310A) antibody fragment and a 20-h in
vivo incubation period. Sections were examined for the
presence of the human Fc portion of the anti-CEA frag-
ment. Intratumoral staining was largely localized to
tumor cells at the periphery of the microtumor nodules
surrounded by stroma and vessels (Figure 5). In compar-
ison, the positive control slide showed membrane stain-
ing of all cancer cells regardless of location with respect
to stroma and vessels as would be expected from an ex
vivo application of the primary anti-CEA antibody. The
negative control section exhibited no staining.
Discussion
Targeting cancer with antibodies is a rapidly expanding
field seeking to provide new technology for diagnosis
Figure 3 Representative slides of IHC staining with anti-CEA scFv-Fc (H310A) antibody of different tissue specimens. At ×40
magnification, (a) human pancreas cancer with strong staining, (b) human pancreas cancer with moderate staining, (c) human pancreas cancer
with weak staining, (d) mouse pancreas cancer xenograft, (e) normal human pancreas, and (f) normal human liver.
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and therapy. Considering molecular imaging applications
such as immunoPET, intact antibodies are limited due
to their extended serum persistence resulting in a high
background signal. However, the growing knowledge of
antibody interactions with FcRN receptors resulting in
prolonged serum persistence have allowed for develop-
ment of engineered antibody fragments possessing
shorter half-lives while providing the same specific bind-
ing to their antigen. In such a way, these engineered
antibodies can overcome the limitations of intact antibo-
dies. Indeed, many recent studies have demonstrated
that smaller size antibody fragments as well as decreased
serum persistence are better imaging agents owing to
their improved tumor penetration and rapid blood clear-
ance [4,13-15]. Previously, our group produced and
characterized the anti-CEA scFv-Fc (H310A) antibody
fragment with a significantly reduced serum half-life (27
h) when compared to the intact antibody (> 10 days)
[5]. With this antibody fragment, we sought to demon-
strate the potential of CEA as a target in pancreas can-
cer and to investigate the utility of this fragment in
antigen-specific targeting within our pancreas cancer
models.
CEA serum levels have been used clinically for many
years to diagnose, stage, and follow patients with color-
ectal cancer. Although CEA serum levels are not widely
elevated in pancreatic cancer, this antigen is expressed
on the cell surface of the vast majority of pancreatic
cancers. Many reports of CEA on pancreas cancer speci-
mens describe expression ranging from 70% to 98%
Capan-1 HPAF-IIBxPC3
A B C
BxPC3 Capan-1 HPAF-II
Positive tumor 2.82 (1.12) 2.66 (0.13) 2.16 (0.44)
Negative tumor 0.16 (0.05) 0.14 (0.15) *
Blood 0.54 (0.14) 0.71 (0.12) 0.68 (0.07)
D
Each image independently scaled.  Images are not corrected for isotope decay
Figure 4 MicroPET and MicroCT images of a representative mouse from each group at 20 h. After tail vein injection showing targeting of
each xenograft with the anti-CEA scFv-Fc (H310A) antibody fragment. Note CEA-positive xenografts (arrow) were not in the same plane as CEA-
negative xenografts although present on all mice except HPAF tumor bearing mice. (a) BxPC3 tumor xenograft mouse, (b) Capan-1 tumor
xenograft mouse, (c) HPAF-II tumor xenograft mouse. (d) Table with the corresponding measured radioactivity of each tissue. Values are
represented as percent of injected dose per gram of tissue (%ID/g).
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[7,8,16]. In addition to showing high CEA expression on
pancreatic cancer cell lines, Kaushal et al. demonstrated
tumor targeting of a fluorophore-conjugated intact anti-
CEA antibody in a xenograft model of pancreas cancer
with the aim of developing an intraoperative imaging
probe [16]. Given the reported prevalent expression of
CEA in pancreas cancers, we attempted to investigate
the immunoPET imaging potential of the anti-CEA
scFv-Fc (H310A) antibody fragment in pancreas cancer
xenograft models. First, we confirmed high levels of
expression on Capan-1, HPAF-II, and BxPC3 cancer cell
lines and no expression of CEA on the MiaPaca-2 cell
line. Additionally, we found that CEA expression was
very similar between the positive CEA cell lines ranging
from 230,000 to 310,000 antigens per cell. Next, utilizing
a tissue microarray we simultaneously evaluated 107
surgically resected human pancreas cancer specimens
for CEA expression with IHC to validate previous
reports and compare with our xenograft models. We
found moderate to strong staining of CEA on 84% of
specimens consistent with results described in the litera-
ture [7,8,16]. Moreover, we demonstrated similar stain-
ing intensity between our mouse pancreatic xenografts
and strongly stained human pancreas cancer specimens.
Based on these results, we were satisfied that CEA is
abundantly expressed in the majority of pancreas
DC
BA
Figure 5 Immunolocalization of anti-CEA scFv-Fc (H310A) antibody fragment after tail vein injection into HPAF-II tumor-bearing mice.
At ×20 magnification, (a) H&E-stained section, (b) negative control; slide incubated with only with secondary HRP-conjugated goat anti-mouse
IgG (Fc specific) antibody, (c) positive control; slide incubated with primary mouse anti-CEA antibody and secondary HRP-conjugated goat anti-
mouse IgG (Fc specific) antibody, (d) slide incubated with mouse anti-human IgG (Fc specific) antibody and HRP-conjugated goat anti-mouse
IgG (Fc specific) antibody.
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cancers and thus a suitable target. Furthermore, our
xenograft model recapitulates the human condition with
respect to CEA expression.
Using our pancreatic cancer mouse xenograft model,
we injected mice with 124I-labeled anti-CEA scFv-Fc
(H310A) antibody and imaged at 4 and 20 h after injec-
tion with microPET/CT. Our microPET images at 4 h
demonstrate quick targeting of the antibody fragment to
all CEA-positive pancreatic tumors (data not shown).
Moreover, microPET images at 20 h show persistence of
signal at the site of the tumor with low blood back-
ground signal. Accordingly, biodistribution data at 20 h
after injection provides objective confirmation of the
microPET images. We were able to achieve positive
tumor to negative tumor ratios greater than 17 demon-
strating antigen-specific tumor targeting of the anti-CEA
scFv-Fc (H310A) antibody fragment. Furthermore, a
tumor to blood ratio of 4.0 at 20 h is evidence of the
imaging benefit afforded by the decreased serum half-
life of the fragment. Overall, these data are very suppor-
tive regarding the immunoPET imaging potential of the
anti-CEA scFv-Fc (H310A) antibody fragment in pan-
creas cancer.
To assess the potential ability of converting an anti-
body-based imaging agent into a tumor-targeting thera-
peutic, we additionally wanted to define the microscopic
pattern of tumor targeting of the anti-CEA scFv-Fc
(H310A) antibody fragment in mice xenografts by per-
forming “immunolocalization” studies. These studies
provided confirmatory evidence of the microPET images
demonstrating the physical presence of the anti-CEA
scFv-Fc (H310A) antibody protein in the tumor sections.
Furthermore, the intratumoral staining pattern demon-
strated localization of antibody to the periphery of
microscopic tumor nodules comprising the macroscopic
tumor xenograft with antibody penetration approxi-
mately one- to five-cell-layers deep from the intervening
stroma and vessels. Additionally, antibody tumor pene-
tration models describe a number of factors including
antigen density, antibody binding affinity, and antibody
metabolism along with physical properties of the cancer
tissue (e.g. tumor vascularity) as impacting antibody
localization [17-21]. Depending on the cytotoxic bystan-
der effect of the therapeutic modality associated with
the antibody fragment, extensive tumor penetration may
not be necessary [19,22,23]. With respect to radioimmu-
notherapy, radionuclides such as Yttrium-90 possessing
a relatively long radiation range (path length > 1 mm)
may supply a sufficient dose of cytotoxic radiation to
the nuclei of cells in center or cold area of the tumor
micronodules which are not directly bound by the anti-
body fragment-radionuclide conjugate [23]. Additionally,
switching to a radiometal with shorter beta particle
range might be more appropriate in considering
treatment of smaller tumor deposits such as microme-
tastases. Although utilizing biodistribution data from
using a radioiodine labeled antibody fragment to esti-
mate biodistribution of a radiometal labeled fragment
was not performed, one can imagine based on the
immunohistochemical staining pattern that a radiola-
beled engineered antibody with modest tumor penetra-
tion, as demonstrated in this study with the anti-CEA
scFv-Fc (H310A) antibody, may have applications for
radioimmunotherapy. Future studies should be directed
at determining the appropriate radionuclide (e.g. alpha-
emitter, long- or short-path-length beta-emitter) suffi-
cient to provide the bystander effect without compro-
mising surrounding tissues.
This work demonstrates the utility of the anti-CEA
scFv-Fc (H310A) antibody fragment for imaging pan-
creas cancer with possible applications for therapy. We
show the in vivo imaging potential and targeting cap-
ability of this antibody fragment in pancreatic cancer
xenografts. Although CEA expression appears to be
similar between our xenografts and the majority of
human pancreas cancer specimens, data from xenograft
models are limited secondary to lack of a competent
immune system. Historically, the majority of murine
monoclonal antibodies have failed to be translated to
the clinical setting because of the human anti-mouse
antibody (HAMA) response. This resulted in the advent
of chimeric antibodies with murine variable regions (VL
and Vh) and human constant domains (CH2 and CH3)
as well as humanized and fully human antibodies. Of
note, the anti-CEA scFv-Fc (H310A) antibody fragment
is a chimeric protein, which should decrease the inci-
dence of the HAMA response, although it may still
occur with repeated administration of the protein [24].
In summary, antigen-specific molecular imaging has
the potential to provide a more accurate assessment of
the tumor burden for pancreatic cancer patients. CEA is
strongly expressed in the majority of pancreas cancers
and thus is a potential target for antibody-based mole-
cular imaging and therapy. Using the novel mutated
anti-CEA scFv-Fc (H310A) antibody fragment with a
reduced serum half-life, we demonstrated in vivo anti-
gen-specific molecular imaging. Furthermore, we define
the microscopic pattern of tumor targeting which may
have implications regarding radioimmunotherapy. The
versatility of this antibody construct, based on the pre-
sence or absence of an Fc domain mutation, provides
for improved pharmacokinetics in both imaging and
therapy making it a very attractive fragment for contin-
ued study and development.
Acknowledgements
Funding support was provided by the Veterans Affairs Career Development
Award (James S. Tomlinson). We thank Waldemar Ladno for his assistance
Girgis et al. EJNMMI Research 2011, 1:24
http://www.ejnmmires.com/content/1/1/24
Page 9 of 10
with the animal studies and Felix Bergara, MS, for his technical assistance.
We would also like to acknowledge the UCLA Translation Pathology Core
Laboratory for their immunostaining services and the UCLA Small Animal
Imaging Resource Program (NIH CA 92865). Flow cytometry was performed
in the UCLA Jonsson Comprehensive Cancer Center (JCCC) and Center for
AIDS Research Flow Cytometry Core Facility, supported by NIH awards CA-
16042 and AI-28697.
Author details
1Department of Surgery, UCLA, 10833 LeConte Ave, Rm 54-140, Los Angeles,
CA 90095, USA 2Crump Institute for Molecular Imaging, Department of
Molecular and Medical Pharmacology, UCLA, Rm 4324E, CNSI, Bldg 114, 570
Westwood Pl, Los Angeles, CA 90095, USA 3Department of Surgery, Veterans
Affairs, Greater Los Angeles, 11301 Wilshire Blvd, Bldg 500, Los Angeles, CA
90073, USA
Authors’ contributions
MG carried out immunoassays, biochemical characterization, functional
characterization and drafted the manuscript. TO participated in animal
studies and manuscript preparation. VK participated in design of the study
and animal studies. KM participated in animals studies and biochemical
characterization. AM participated in design of the study and manuscript
preparation. JT performed animal studies, carried out immunoassays,
conceived the study and helped prepare the manuscript. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 17 June 2011 Accepted: 7 November 2011
Published: 7 November 2011
References
1. American Cancer Society: Cancer facts and figures. (2011) Retrieved 2011
[http://www.cancer.org/Research/CancerFactsFigures/index].
2. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin
2010, 60:277-300.
3. DeVita VT, Hellman S, Rosenberg SA: Cancer, principles & practice of
oncology. Philadelphia: Lippincott Williams & Wilkins;, 7 2005.
4. Kenanova V, Wu AM: Tailoring antibodies for radionuclide delivery. Expert
Opin Drug Deliv 2006, 3:53-70.
5. Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH,
Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS, Williams LE, Shively JE,
Colcher D, Raubitschek AA, Wu AM: Tailoring the pharmacokinetics and
positron emission tomography imaging properties of anti-
carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer
Res 2005, 65:622-631.
6. Hammarstrom S: The carcinoembryonic antigen (CEA) family: structures,
suggested functions and expression in normal and malignant tissues.
Semin Cancer Biol 1999, 9:67-81.
7. Albers GH, Fleuren G, Escribano MJ, Nap M: Immunohistochemistry of CEA
in the human pancreas during development, in the adult, chronic
pancreatitis, and pancreatic adenocarcinoma. Am J Clin Pathol 1988,
90:17-22.
8. Allum WH, Stokes HJ, Macdonald F, Fielding JW: Demonstration of
carcinoembryonic antigen (CEA) expression in normal, chronically
inflamed, and malignant pancreatic tissue by immunohistochemistry. J
Clin Pathol 1986, 39:610-614.
9. Yamaguchi K, Enjoji M, Tsuneyoshi M: Pancreatoduodenal carcinoma: a
clinicopathologic study of 304 patients and immunohistochemical
observation for CEA and CA19-9. J Surg Oncol 1991, 47:148-154.
10. Galfre G, Milstein C: Preparation of monoclonal antibodies: strategies and
procedures. Methods Enzymol 1981, 73:3-46.
11. Defrise M, Kinahan PE, Townsend DW, Michel C, Sibomana M, Newport DF:
Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans
Med Imaging 1997, 16:145-158.
12. Loening AM, Gambhir SS: AMIDE: a free software tool for multimodality
medical image analysis. Mol Imaging 2003, 2:131-137.
13. Beckman RA, Weiner LM, Davis HM: Antibody constructs in cancer
therapy: protein engineering strategies to improve exposure in solid
tumors. Cancer 2007, 109:170-179.
14. Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA,
Williams LE, Chatziioannou AF, Gambhir SS, Wu AM: 124I-labeled
engineered anti-CEA minibodies and diabodies allow high-contrast,
antigen-specific small-animal PET imaging of xenografts in athymic
mice. J Nucl Med 2003, 44:1962-1969.
15. Yazaki PJ, Wu AM, Tsai SW, Williams LE, Ikler DN, Wong JY, Shively JE,
Raubitschek AA: Tumor targeting of radiometal labeled anti-CEA
recombinant T84.66 diabody and t84.66 minibody: comparison to
radioiodinated fragments. Bioconjug Chem 2001, 12:220-228.
16. Kaushal S, McElroy MK, Luiken GA, Talamini MA, Moossa AR, Hoffman RM,
Bouvet M: Fluorophore-conjugated anti-CEA antibody for the
intraoperative imaging of pancreatic and colorectal cancer. J Gastrointest
Surg 2008, 12:1938-1950.
17. Ackerman ME, Pawlowski D, Wittrup KD: Effect of antigen turnover rate
and expression level on antibody penetration into tumor spheroids. Mol
Cancer Ther 2008, 7:2233-2240.
18. Thurber GM, Schmidt MM, Wittrup KD: Antibody tumor penetration:
transport opposed by systemic and antigen-mediated clearance. Adv
Drug Deliv Rev 2008, 60:1421-1434.
19. Thurber GM, Schmidt MM, Wittrup KD: Factors determining antibody
distribution in tumors. Trends Pharmacol Sci 2008, 29:57-61.
20. Thurber GM, Zajic SC, Wittrup KD: Theoretic criteria for antibody
penetration into solid tumors and micrometastases. J Nucl Med 2007,
48:995-999.
21. Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W,
Weinstein JN: Micropharmacology of monoclonal antibodies in solid
tumors: direct experimental evidence for a binding site barrier. Cancer
Res 1992, 52:5144-5153.
22. Prestwich WV, Nunes J, Kwok CS: Beta dose point kernels for
radionuclides of potential use in radioimmunotherapy. J Nucl Med 1989,
30:1036-1046.
23. Humm JL: Dosimetric aspects of radiolabeled antibodies for tumor
therapy. J Nucl Med 1986, 27:1490-1497.
24. Presta LG: Engineering of therapeutic antibodies to minimize
immunogenicity and optimize function. Adv Drug Deliv Rev 2006,
58:640-656.
doi:10.1186/2191-219X-1-24
Cite this article as: Girgis et al.: Targeting CEA in Pancreas Cancer
Xenografts with a Mutated scFv-Fc Antibody Fragment. EJNMMI Research
2011 1:24.
Submit your manuscript to a 
journal and benefi t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the fi eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Girgis et al. EJNMMI Research 2011, 1:24
http://www.ejnmmires.com/content/1/1/24
Page 10 of 10
